Login · Contact

Akorn Investor Relations

INVESTOR RELATIONS

Investor Relations Stock Quote & Chart Press Releases Events & Presentations SEC Filings Annual Reports Analyst Coverage Corporate Governance Investor FAQs IR Contacts Contact Us

Tool Kit

E-mail Alerts Print Page RSS Feeds

Press Releases

Date	Title
11/06/18	Akorn Provides Third Quarter 2018 Results LAKE FOREST, Ill. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its financial results for the third quarter of 2018. Business Highlights Revenues declined predominantly due to the effect of competition on key
10/29/18	Akorn Receives Product Approval LAKE FOREST, Ill. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that, on October 26, 2018 , it received a new Abbreviated New Drug Application (ANDA) approval from the U.S.
10/18/18	Akorn Appeals Fresenius Kabi Ruling LAKE FOREST, Ill. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that the company filed a notice of appeal to the Supreme Court of the State of Delaware from the recent decision of the Delaware Court of Chancery
10/10/18	Akorn Receives Product Approval LAKE FOREST, Ill. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it has received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration ( FDA ) for Bimatoprost
10/01/18	Akorn Comments on Delaware Chancery Court Ruling LAKE FOREST, Ill. --(BUSINESS WIRE)--Oct. 1, 2018-- Akorn, Inc. (NASDAQ:AKRX), today issued the following statement in response to the ruling by the Delaware Chancery Court on the complaint filed by Akorn against Fresenius Kabi AG : “We are disappointed by the ruling by the Delaware Chancery Court
04/23/18	Akorn Asks Delaware Court to Require Fresenius Kabi to Fulfill Its Obligations under Merger Agreement LAKE FOREST, Ill. --(BUSINESS WIRE)--Apr. 23, 2018-- Akorn, Inc. (NASDAQ:AKRX), today filed a complaint in Delaware Chancery Court asking that Fresenius Kabi AG be required to fulfill its obligations under the definitive merger agreement, and issued the following statement: “Fresenius’ attempt to
04/22/18	Akorn Issues Statement LAKE FOREST, Ill. --(BUSINESS WIRE)--Apr. 22, 2018-- Akorn, Inc. (NASDAQ:AKRX), today issued a statement in response to Fresenius Kabi’s announcement that it is seeking to terminate the definitive merger agreement announced on April 24, 2017 . “We categorically disagree with Fresenius’ accusations.
02/26/18	Akorn Issues Statement on Investigation LAKE FOREST, Ill. , Feb. 26, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today issued the following statement: “Akorn and Fresenius Kabi AG, with the assistance of outside consultants, are investigating alleged breaches of FDA data